

**Minnesota Department of Human Services
DUR Board Meeting**

May 15, 2024

Members Present

Arnes Huskic, M.D. and Ann Philbrick, PharmD.

DHS Staff Present

Mary Beth Reinke, PharmD., DUR Coordinator.

Other Attendants

Cory Chambliss, Kepro, Alena Mitchell, PharmD, Kepro, and Ariane Casey, Pharm.D., Kepro.

Public Comments: There were no public comments.

Approval of Minutes: This was moved to the next meeting.

Old business:

The Overuse of Controlled Substances intervention was mailed May 14, 2024, consisting of 161 provider letters regarding 446 patients.

The Psychotropic Drugs in Adults Intervention was mailed April 12, 2024, consisting of 684 provider letters regarding 1,249 patients receiving 3 or more psychotropic medication. For the second-generation antipsychotics (SGA) blood glucose and lipid monitoring, there were 1,355 provider letters regarding 3,211 patients (blood glucose) and 894 provider letters regarding 1,455 patients (lipids).

New business:

RetroDUR intervention evaluations presented occurred during Federal-Fiscal-Year (FFY) 2023.

1. SUPPORT Act #2 Evaluation

For the pre-intervention baseline period, January 27, 2023, to July 26, 2023, 677 prescribers received letters regarding 374 patients. A patient could have more than one clinical indicator. In the post-intervention period, there were 312 adjusted targeted patients. The overall occurrences on clinical indicators decreased by 43.5%. The six-month estimated savings was \$38,040.12 which was \$20.32 savings per recipient per month.

2. Psychotropic Drugs in Youth #2 Evaluation

For the pre-intervention baseline period, March 17, 2023, to September 12, 2023, 1,844 prescribers received letters regarding 2,598 distinct targeted patients. A patient could have more than one clinical indicator. In the post-intervention period, there were 2,456 adjusted targeted patients. Overall, clinical indicators improved by 46.98%. The six-month estimated savings was \$530,167.94 which was \$35.98 savings per recipient per month.

3. Psychotropics in Adults Evaluation

Pre-intervention baseline period, December 17, 2022, to June 15, 2023, consisted of 3,377 prescriber letters regarding 3,693 distinct targeted patients. In the post-intervention period, there were 3,334 adjusted prescribers and 2,978 adjusted targeted patients. Overall clinical indicators occurrences

improved by 41.95%. The six-month estimated savings was \$906,902.10 which was \$50.76 savings per recipient per month.

4. Diabetes Management Evaluation

For the October 18, 2023, mailing, there were 626 adjusted targeted patients and 818 adjusted targeted prescribers in the six-month post intervention period. Overall, clinical indicator improvement was 88.46% and the six-month estimated cost savings was \$362,294.

The meeting was adjourned.